Crestor generic
Pro Research Analysisby 
Searched over 200M research papers for "crestor generic"
Consensus Meter
Crestor Generic: Insights and Implications
AstraZeneca's Legal Actions Against Generic Manufacturers
AstraZeneca has taken legal action against seven generic manufacturers—Aurobindo, Apotex, Cobalt, Par, Sandoz, Mylan, and Sun—who have applied to the US FDA to market generic versions of Crestor (rosuvastatin). These companies argue that Crestor’s patent, licensed from Shionogi, is either invalid, unenforceable, or not infringed. Despite other statins like Zocor and Pravachol coming off-patent, Crestor’s patent is set to expire in 2016, potentially maintaining AstraZeneca’s earnings due to Crestor’s effectiveness in reducing arterial plaque buildup in atherosclerosis.
Comparative Efficacy and Safety of Generic Rosuvastatin
A study conducted by the Russian Scientific Medical Society of Internal Medicine compared the efficacy and safety of the generic rosuvastatin compound Akorta with the original Crestor. The study included 60 patients with dyslipidemia and found that both drugs were comparable in reducing LDL cholesterol levels and achieving target LDL-C levels. The safety profiles of both drugs were also similar, indicating that the generic version is as effective and safe as the original Crestor for dyslipidemia correction.
Impact of Lipitor’s Patent Expiration on Crestor Demand
The expiration of Lipitor’s patent did not significantly affect the overall market for Crestor. However, there was a notable reduction in Crestor usage among patients with private insurance and Medicaid. Specifically, private insurance patients reduced their Crestor usage by about 13%, and Medicaid patients also showed a significant reduction. Additionally, there was an 18% increase in the strength of a typical Crestor pill, which could be seen as a de facto price decrease for Crestor.
Clinical Efficacy of Crestor in Treating Atherosclerosis
Crestor has shown promising results in treating atherosclerosis by significantly lowering LDL cholesterol levels and potentially increasing HDL levels. The ASTEROID study highlighted that Crestor led to a significant regression of atherosclerosis, although the study lacked a placebo or comparator group for ethical reasons. These findings suggest that Crestor could be part of a paradigm shift in the treatment of atherosclerosis, especially when compared to other statins like high-dose Lipitor, which has been shown to halt the progression of the disease.
Rosuvastatin’s Favorable Impact on Lipid Profile
Rosuvastatin (Crestor) has been demonstrated to have a more favorable impact on the lipid profile compared to other statins. It is associated with a greater reduction in total and LDL cholesterol levels and a greater increase in HDL cholesterol concentration. In phase III clinical trials, nearly 80% of patients treated with the usual 10 mg dosage of rosuvastatin achieved LDL cholesterol levels below the recommended targets. The safety profile of rosuvastatin is comparable to other commercialized statins, making it a reliable option for treating primary hypercholesterolemia or combined dyslipidemia.
Conclusion
The introduction of generic versions of Crestor has led to significant legal and market dynamics. While AstraZeneca continues to defend its patent, studies show that generic rosuvastatin is as effective and safe as the original. The expiration of patents for other statins like Lipitor has influenced Crestor’s market demand, particularly among insured patients. Clinically, Crestor remains a potent option for managing cholesterol levels and treating atherosclerosis, with a favorable impact on lipid profiles and a comparable safety profile to other statins.
Sources and full results
Most relevant research papers on this topic